Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 24, 2022

Primary Completion Date

March 1, 2023

Study Completion Date

March 1, 2026

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Furmonertinib+cisplating/pemetrexed

Furmonertinib 80mg/d for 9 weeks and cisplating75mg/m2 d1 iv + pemetrexed 500mg/m2 d1 iv in 21-day cycles for 3 cycles

Trial Locations (1)

RECRUITING

Tangdu Hospital, Xi'an

All Listed Sponsors

lead

Tang-Du Hospital

OTHER